Literature DB >> 25061847

Developmental programming: prenatal steroid excess disrupts key members of intraovarian steroidogenic pathway in sheep.

Vasantha Padmanabhan1, Natalia R Salvetti, Valentina Matiller, Hugo H Ortega.   

Abstract

Prenatal testosterone (T) excess disrupts ovarian cyclicity and increases circulating estradiol levels as well as follicular recruitment and persistence culminating in multifollicular ovary similar to women with polycystic ovary syndrome. We tested whether prenatal T excess, by androgenic or estrogenic action, disrupts the steroid biosynthetic machinery in sheep in a cell-, follicle stage-, age-, and treatment-specific manner consistent with the ovarian disruptions and increased estradiol release. Impact of T/dihydrotestosterone (DHT) treatments from days 30-90 of gestation on steroidogenic acute regulatory protein, 3β-hydroxysteroid dehydrogenase, cytochrome P-450 17α-hydroxylase/C17, 20-lyase (CYP17A1), and cytochrome P-450 aromatase (CYP19A1) were examined on fetal day 90, 140 and 10 months (postpubertal), and 21 months (adult, no DHT group) of age by immunohistochemistry. All 4 markers changed in a cell-, follicle stage-, and age-specific manner. Both treatments increased steroidogenic acute regulatory protein expression in preantral follicles of postpubertal and adult females. Effects of prenatal T and DHT on 3β-hydroxysteroid dehydrogenase differed in a follicle- and age-specific manner. CYP17A1 was reduced in the theca interna of antral follicles by T, but not DHT, in 10- and 21-month-old females. CYP19A1 was reduced by both T and DHT at all ages barring an increase on fetal day 140. Reduced granulosa CYP19A1 and thecal CYP17A1 in adults likely disrupt the intrafollicular androgen/estrogen balance contributing to follicular persistence. The reduced thecal CYP17A1 expression suggests that the hyperandrogenic ovarian phenotype may originate from increased enzyme activity or alternatively via a different isoform of CYP17. The reduced CYP19A1 in antral follicles of adults indicates that the increased circulating estradiol release likely arises from the increased number of persisting follicles.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25061847      PMCID: PMC4138569          DOI: 10.1210/en.2014-1266

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  65 in total

Review 1.  Steroid 11 beta-hydroxylase deficiency and related disorders.

Authors:  P C White
Journal:  Endocrinol Metab Clin North Am       Date:  2001-03       Impact factor: 4.741

2.  Maternal use of oral contraceptives and risk of fetal death.

Authors:  Rikke Jellesen; Katrine Strandberg-Larsen; Tina Jørgensen; Jørn Olsen; Ane M Thulstrup; Anne-Marie N Andersen
Journal:  Paediatr Perinat Epidemiol       Date:  2008-07       Impact factor: 3.980

3.  Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries.

Authors:  A J Jakimiuk; S R Weitsman; A Navab; D A Magoffin
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

4.  The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome.

Authors:  V L Nelson; K N Qin; R L Rosenfield; J R Wood; T M Penning; R S Legro; J F Strauss; J M McAllister
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

5.  Ontogeny of steroidogenesis in the fetal sheep gonad.

Authors:  L D Quirke; J L Juengel; D J Tisdall; S Lun; D A Heath; K P McNatty
Journal:  Biol Reprod       Date:  2001-07       Impact factor: 4.285

6.  Cell-specific expression of immunoreactive cholesterol side-chain cleavage cytochrome P-450 during follicular development in the rat ovary.

Authors:  T Zlotkin; Y Farkash; J Orly
Journal:  Endocrinology       Date:  1986-12       Impact factor: 4.736

Review 7.  Current concepts in the polycystic ovary syndrome.

Authors:  A Dunaif; A Thomas
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

8.  Developmental programming: differential effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, depletion of follicular reserve, and ovarian morphology in sheep.

Authors:  Peter Smith; Teresa L Steckler; Almudena Veiga-Lopez; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2008-12-17       Impact factor: 4.285

9.  Developmental programming: prenatal androgen excess disrupts ovarian steroid receptor balance.

Authors:  Hugo H Ortega; Natalia R Salvetti; Vasantha Padmanabhan
Journal:  Reproduction       Date:  2009-03-04       Impact factor: 3.906

Review 10.  Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans.

Authors:  Shanna H Swan
Journal:  Environ Res       Date:  2008-10       Impact factor: 6.498

View more
  14 in total

Review 1.  Steroidogenic versus Metabolic Programming of Reproductive Neuroendocrine, Ovarian and Metabolic Dysfunctions.

Authors:  Rodolfo C Cardoso; Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Neuroendocrinology       Date:  2015-04-01       Impact factor: 4.914

2.  Developmental programming: prenatal testosterone-induced epigenetic modulation and its effect on gene expression in sheep ovary†.

Authors:  Niharika Sinha; Sambit Roy; Binbin Huang; Jianrong Wang; Vasantha Padmanabhan; Aritro Sen
Journal:  Biol Reprod       Date:  2020-04-24       Impact factor: 4.285

3.  Prenatal programming by testosterone of follicular theca cell functions in ovary.

Authors:  Danielle Monniaux; Carine Genêt; Virginie Maillard; Peggy Jarrier; Hans Adriaensen; Christelle Hennequet-Antier; Anne-Lyse Lainé; Corinne Laclie; Pascal Papillier; Florence Plisson-Petit; Anthony Estienne; Juliette Cognié; Nathalie di Clemente; Rozenn Dalbies-Tran; Stéphane Fabre
Journal:  Cell Mol Life Sci       Date:  2019-07-20       Impact factor: 9.261

Review 4.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

5.  Developmental Programming: Gestational Exposure to Excess Testosterone Alters Expression of Ovarian Matrix Metalloproteases and Their Target Proteins.

Authors:  Muraly Puttabyatappa; Ashleigh Irwin; Jacob D Martin; Makeda Mesquitta; Almudena Veiga-Lopez; Vasantha Padmanabhan
Journal:  Reprod Sci       Date:  2017-03-16       Impact factor: 3.060

6.  Developmental Programming: Contribution of Epigenetic Enzymes to Antral Follicular Defects in the Sheep Model of PCOS.

Authors:  Xingzi Guo; Muraly Puttabyatappa; Robert C Thompson; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2019-10-01       Impact factor: 4.736

7.  INSIGHTS ON AROMATASE IMMUNOHISTOCHEMISTRY: VARIATIONS BETWEEN INTRINSIC MOLECULAR SUBTYPES OF BREAST CANCERS.

Authors:  I Armasu; C Preda; V Ianole; V Mocanu; I Hristov; E C Andriescu; I Cretu-Silivestru; I Vasiliu; C G Dascalu; C D Lupascu; I Crumpei; D N Serban; I L Serban; D G Ciobanu Apostol
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

Review 8.  Developmental Programming of Ovarian Functions and Dysfunctions.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Vitam Horm       Date:  2018-02-22       Impact factor: 3.421

9.  Developmental Programming: Prenatal Testosterone Excess on Ovarian SF1/DAX1/FOXO3.

Authors:  Muraly Puttabyatappa; Valentina Matiller; Antonela F Stassi; Natalia R Salvetti; Hugo H Ortega; Vasantha Padmanabhan
Journal:  Reprod Sci       Date:  2020-01-01       Impact factor: 3.060

10.  Developmental Programming: Sheep Granulosa and Theca Cell-Specific Transcriptional Regulation by Prenatal Testosterone.

Authors:  Muraly Puttabyatappa; Xingzi Guo; John Dou; Daniel Dumesic; Kelly M Bakulski; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.